Canadian Blood Services (CBS) Announces the Results of the Request for Proposals (RFP) for Plasma-Derived Plasma Protein and Related Products (PPRP).
Through their formulary, CBS provides many patients across Canada, including patients with HAE, with a wide variety of treatments. This formulary is updated on a regular basis to remain current and relevant. CBS asked various stakeholders to support this process by participating in their RFP selection committee; this committee included a member of the HAE Canada Board of Directors. The RFP selection committee has completed their review of vendor submissions and CBS posted the results on their website. We’d like to thank our Board member who contributed their time and expertise to this process.
We’d like to draw your attention to the section pertaining to HAE treatments:
C1-Esterase Inhibitor (C1-INH): All current C1-INH products will be on formulary with no restrictions except for Cinryze®. Cinryze® will no longer be carried on the formulary. Patients using Cinryze® will need to be switched to a different product once inventory is depleted.
If you have questions regarding CBS’s announcement, we encourage you to contact your HAE physician to discuss your treatment options.
Please CLICK HERE to find the customer letter, dated September 20, 2022, to learn further RFP result details. (found under Hospital Services / Customer Service / Communications / Customer Letters)